Light Chain Deposition Disease: A Morphological Case Report

Hristo Popov 1, George S. Stoyanov 2, 1, Peter Ghenev 1

1. General and Clinical Pathology/Forensic Medicine and Deontology, Medical University of Varna, Varna, BGR
2. General and Clinical Pathology, St. Marina University Hospital, Varna, BGR

Corresponding author: Hristo Popov, popov12@abv.bg

Abstract
Light chain deposition disease (LCDD) is a rare condition associated with the overproduction and deposition of monoclonal light chain immunoglobulins. The kidneys are universally affected in LCDD, with the development of renal failure with nephrotic syndrome, microscopic hematuria, and proteinuria. Most cases are associated with a plasma cell neoplasm (multiple myeloma or plasmacytoma) or other lymphoproliferative disorders, with a reasonable number of cases also being idiopathic. Other organs can be affected in rare cases, without producing significant symptoms, predominantly the liver and heart. In this report, we discuss a case of a 72-year-old female presenting with the aforementioned symptoms.

Percutaneous ultrasound-guided kidney biopsy revealed nodular sclerosis with periodic acid-Schiff stain (PAS)-positive, Congo red-negative, silver impregnation weakly-positive, and Masson's trichrome-positive (red reaction) deposits with ribbon-like changes together with light chain deposits in the tubular basement membranes. As LCDD was diagnosed, the patient was subjected to further tests, with multiple myeloma of the thoracic vertebrae also being diagnosed. The patient was started on myeloma treatment; however, she subsequently developed a severe lower limb infection that required amputation, after which she developed sepsis and expired.

Categories: Pathology, Nephrology, Hematology
Keywords: multiple myeloma, case report, kidney, nephropathology, monoclonal immunoglobulin deposition disease, light chain deposition disease

Introduction
Light chain deposition disease (LCDD) is the most common variant of monoclonal immunoglobulin deposition disease, which is characterized by light chain immunoglobulin deposition in the tissues of the body [1]. While the immunoglobulin deposition may be diffuse, the kidneys are always affected, with only a minority of cases developing extrarenal involvement [2].

The condition was first described in 1976 in two patients with end-stage renal disease and, due to its rarity, its exact incidence is unknown in the general population [3]. Based on the largest collected cohort to date by Pozzi et al., involving an analysis of 63 patients, the average age of diagnosis is 58 years, with other smaller studies estimating it as follows: 56 years, Sayed et al. in 53 patients; 51 years, Li et al. in 48 patients; and 56 years, Nasr et al. in 64 patients (some of which are with heavy chain deposition), with males being affected more often than females [2,4-6].

LCDD develops due to the overproduction and thereby the deposition of abnormal immunoglobulins, with around 60% of cases developing in the context of multiple myeloma/plasmacytoma and other lymphoproliferative disorders; however, in a large number of cases (up to 30% in some studies), an underlying cause cannot be identified - idiopathic LCDD [2]. Light chain deposits can develop in any other extrarenal site but are usually rare and characterized by an indolent clinical course, the liver and heart being the most common secondary sites [7]. Furthermore, some patients have concomitant cast nephropathy caused by the monoclonal proteins leading to acute renal damage. Clinically, LCDD presents with renal failure, proteinuria, microscopic hematuria, and nephrotic syndrome [8].

Case Presentation
We report the histopathological findings in a 72-year-old female presenting with nephrotic syndrome, long-term hypertension, pretilial edema, and grade II obesity. Urinalysis reported proteinuria (5.5 grams per liter), microscopic hematuria, and creatinine of 940 µmol per liter. Blood tests reported hemoglobin levels of 96 g/l (anemia), and all other results were within the reference range. Based on her symptoms and laboratory findings, the patient was scheduled for a percutaneous kidney biopsy with a 16-G needle under ultrasound guidance.

Histology and histochemistry initially showed nodular sclerosis with mesangial deposits being periodic acid-Schiff stain (PAS)-positive, Congo red-negative, and having a weak reaction to silver impregnation, which
also underlined ribbon-like thickened tubular basement membranes (Figures 1A-1C). The mesangial deposits were also Masson’s trichrome-positive (red reaction), suggesting their immunoglobulin nature (Figure 1D). Immunofluorescence showed that the deposits in the tubular basement membranes were comprised of lambda chains (Figure 1E).

**FIGURE 1: Late LCDD presenting as nodular glomerulosclerosis**

A: PAS-positive nodular deposits (PAS stain, original magnification 400x). B: The same nodules are Congo-negative (Congo red stain, original magnification 400x). C: The same nodules are weakly positive for silver impregnation, a strong reaction is noted in the basal membrane of the tubular epithelium with ribbon-like change (Silver impregnation (modified method), original magnification 400x). D: Red reaction in nodular glomerular deposits (Masson’s trichrome, original magnification 400x). E: Linear light chain deposition in the tubular basal membranes (direct immunofluorescence, original magnification 400x)

LCDD: light chain deposition disease; PAS: periodic acid-Schiff stain

Based on the morphological findings, the diagnosis of LCDD was established. Secondary urinary analysis revealed Bence-Jones protein in the urine and the patient was scheduled for whole-body CT to establish any foci suggestive of lymphoproliferative disorder. The CT showed osteolytic foci in the fifth, sixth, and seventh thoracic vertebrae. Secondary biopsy of the osteolytic lesions showed a diffuse plasma cell proliferation, positive for cluster of differentiation (CD) 138, and the diagnosis of multiple myeloma with secondary LCDD was established. The patient was started on treatment with bortezomib, dexamethasone, and darbepoetin alfa. However, she developed deep vein thrombosis with an associated severe subcutaneous infection in her left lower limb, requiring distal amputation. Microbiology revealed *Staphylococcus epidermidis*. However, despite sufficient amputation and antimicrobial treatment with cefazolin and metronidazole, the patient expired during the early postoperative period due to developing sepsis three months after the initial diagnosis of LCDD.

**Discussion**

Under light microscopy, early changes in LCDD show discrete mesangial enlargement, with a negative reaction for Congo red, while advanced changes present with nodular sclerosis very similar to type III diabetic nephropathy - Kimmelstiel-Wilson type. Immunofluorescence testing with kappa and lambda chains shows deposits in the mesangium of the glomeruli and along the tubular basement membranes [9]. Under electron microscopy, powdery deposits similar to ground pepper are observed in the basal lamina of the glomerular capillaries and the tubular basal membrane [9].

Due to the condition’s rarity and morphological similarities with other glomerular lesions, the differential diagnosis is challenging and involves a broad set of conditions: diabetic nephropathy, idiopathic nodular glomerulosclerosis, amyloidosis, and cryoglobulinemia, with differential histochemical features as shown in Table 1 [9].
| Condition                        | PAS reaction | Silver impregnation | Congo red | Masson's trichrome | Immunofluorescence         |
|--------------------------------|--------------|---------------------|-----------|-------------------|----------------------------|
| Nodular diabetic glomerulosclerosis | Positive     | Positive            | Negative  | Green reaction    | Linear IgG or negative     |
| Idiopathic nodular glomerulosclerosis | Positive     | Positive            | Negative  | Green reaction    | Negative                   |
| LCDD                            | Positive     | Negative to weak positive | Negative  | Red reaction      | Kappa/lambda               |
| Amyloidosis                     | Weak to moderately positive | Negative  | Positive  | Negative  | Positive                   |
| Cryoglobulinemia                | Positive     | Positive subendothelial deposits | Negative  | Red reaction      | IgG, IgM, C1q, C3, kappa, and lambda |

**TABLE 1: Differential diagnosis and special stain reactions in nodular glomerulosclerosis**

LCDD: light chain deposition disease; PAS: periodic acid-Schiff stain

Immunofluorescence is key in differentiating these conditions, with histochemical reactions being suggestive but not definitive [2,3,7,9].

Clinically, LCDD usually presents with hypertension, microhematuria, and proteinuria in the absence of therapy and its clinical course is one of rapidly progressing chronic kidney disease requiring renal replacement therapy [10]. In the idiopathic form, if a kidney transplant is performed in such cases, the outcomes are generally poor and associated with allograft LCDD, which occurs within a few years of transplantation [11,12].

Based on its broad differential diagnosis and its usual age of onset, LCDD can often be misdiagnosed and therefore underreported. This likelihood is especially high when the patients have concomitant diabetes or new-onset kidney failure in the context of known lymphoproliferative disorders, when it can be interpreted as disease progression or secondary renal involvement by conventional mechanisms.

**Conclusions**

LCDD is a rare condition affecting the kidney and, in rare cases, other organs; it is characterized by lambda light chains being deposited in the glomeruli and basal membrane of the tubular system. Although most commonly associated with multiple myeloma and lymphomas, some cases can be idiopathic. As seen in our case, the renal biopsy, if interpreted properly, can guide toward a detailed exploration and identification of the primary disease, which turned out to be multiple myeloma in our case.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** The authors would like to disclose that one of the authors (George Stoyanov, MD, Ph.D.) was a member of the editorial approval board of the journal (Cureus Journal of Medical Science) at the time of the manuscript submission. The authors affirm that this in no way, shape, or form resulted in manipulating the reviewer selection process, reviews themselves, or the initial or final editorial decision.

**References**

1. Wang Q, Jiang F, Xu G: The pathogenesis of renal injury and treatment in light chain deposition disease. J Transl Med. 2019, 17:387. 10.1186/s12967-019-02147-4
2. Pozzi C, D’Amico M, Fogazzi GB, et al.: Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003, 42:1154-63. 10.1053/ajkd.2003.08.040
3. Randall RE, Williamson WC Jr, Mullinax F, Tung MY, Still WJ: Manifestations of systemic light chain deposition. Am J Med. 1976, 66:295-9. 10.1016/0002-9343(76)90440-x
4. Sayed RH, Wechalekar AD, Gilbertson JA, et al.: Natural history and outcome of light chain deposition disease. Blood. 2015, 126:2805-10. 10.1182/blood-2015-07-658872

5. Li XM, Rui HC, Liang DD, et al.: Clinicopathological characteristics and outcomes of light chain deposition disease: an analysis of 48 patients in a single Chinese center. Ann Hematol. 2016, 95:901-9. 10.1007/s00277-016-2659-1

6. Nasr SH, Valeri AM, Correll LD, Fidler ME, Sethi S, D'Agati VD, Leung N: Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012, 7:231-9. 10.2215/CJN.08640811

7. Ronco PM, Alyanakian MA, Mougenot B, Aucouturier P: Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol. 2001, 12:1558-65.

8. Fogo AB, Lusco MA, Najafian B, Alpers CE: AJKD Atlas of Renal Pathology: light chain deposition disease. Am J Kidney Dis. 2015, 66:e47-8. 10.1053/j.ajkd.2015.10.007

9. Suzuki K: Light- and heavy-chain deposition disease (LHICDD): difficulty in diagnosis and treatment. Intern Med. 2005, 44:915-6. 10.2169/internalmedicine.44.915

10. Pozzi C, Fogazzi GB, Banfi G, Strom EH, Ponticelli C, Locatelli F: Renal disease and patient survival in light chain deposition disease. Clin Nephrol. 1995, 43:281-7.

11. Leung N, Lager DJ, Gertz MA, Wilson K, Kanakiriya S, Fervenza FC: Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis. 2004, 43:147-53. 10.1053/j.ajkd.2003.09.020

12. Short AK, O'Donoghue DJ, Riad HN, Short CD, Roberts IS: Recurrence of light chain nephropathy in a renal allograft. A case report and review of the literature. Am J Nephrol. 2001, 21:237-40. 10.1159/000046254